Jak3 deficiency blocks innate lymphoid cell development

Keyphrases

• Innate Lymphoid Cells 100%
• Innate Lymphoid Cell Development 100%
• JAK3 100%
• Severe Combined Immunodeficiency 60%
• Tofacitinib 60%
• JAK Inhibitors 40%
• ILC1 40%
• ILC3 40%
• PF-06651600 40%
• Natural Killer Cells 20%
• Clinical Trials 20%
• Tyrosine Kinase 20%
• Autosomal Recessive 20%
• Interleukin-22 (IL-22) 20%
• Clinical Efficacy 20%
• Cell Differentiation 20%
• Bone Marrow 20%
• Gain-of-function mutation 20%
• Cell Progenitors 20%
• Immune System 20%
• Spontaneous mutation 20%
• Therapeutic Inhibitors 20%
• Cell Precursors 20%
• Immune-mediated Conditions 20%
• NR1D1 20%
• Antigen-independent 20%
• Active Rheumatoid Arthritis 20%
• JAK3 Inhibitor 20%
• Independent Professionals 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Tofacitinib 100%
• Janus Kinase Inhibitor 66%
• Severe Combined Immunodeficiency 66%
• Rheumatoid Arthritis 33%
• Clinical Trial 33%
• Cytokine 33%
• Protein Tyrosine Kinase 33%
• Immunosuppressive Agent 33%
• Janus Kinase 3 Inhibitor 33%
• Autosomal Recessive Severe Combined Immunodeficiency 33%
• Inflammatory Arthritis 33%

Immunology and Microbiology

• Cell Maturation 100%
• Innate Lymphoid Cell 100%
• Tofacitinib 50%
• Severe Combined Immunodeficiency 33%
• Natural Killer Cell 16%
• Cytokine 16%
• Cell Differentiation 16%
• Immunosuppressive Drug 16%
• Loss of Function Mutation 16%
• Inflammatory Arthritis 16%
• Immune System 16%
• Precursor 16%
• Immunity 16%
• Spontaneous Mutation 16%
• Autosomal Recessive Severe Combined Immunodeficiency 16%